Candel Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Kendrick St Ste 450, Needham, Massac...Phone Number
(617) 916-5445Website
www.candeltx.comRevenue
-Stock Symbol
CADLIndustry
About Candel Therapeutics
Candel Therapeutics is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained anti-cancer effect based on a highly individualized T cell response against the injected tumor and uninjected metastases, and has the potential to change disease outcomes across a variety of indications.Explore more
Candel Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Candel Therapeutics
Compare insights from companies similar to Candel Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Candel Therapeutics Tech Stack
A closer look at the technologies used by Candel Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Candel Therapeutics
Sign Up For FreeTo access detailed company insights
Candel Therapeutics is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained a... Read More
